Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 4,374 shares of Momenta Pharmaceuticals stock in a transaction on Monday, November 12th. The stock was sold at an average price of $13.50, for a total transaction of $59,049.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, August 21st, Craig A. Wheeler sold 1,969 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $27.43, for a total transaction of $54,009.67.

Shares of NASDAQ:MNTA traded down $0.37 during midday trading on Tuesday, reaching $12.78. The company had a trading volume of 322,464 shares, compared to its average volume of 694,048. The company has a market capitalization of $1.03 billion, a P/E ratio of -10.65 and a beta of 2.34. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.72 and a 52-week high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.18. The company had revenue of $14.88 million for the quarter, compared to the consensus estimate of $16.99 million. Momenta Pharmaceuticals had a negative net margin of 158.21% and a negative return on equity of 44.72%. The firm’s quarterly revenue was down 38.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.44) EPS. As a group, analysts predict that Momenta Pharmaceuticals, Inc. will post -2.59 EPS for the current year.

Several large investors have recently modified their holdings of MNTA. Amalgamated Bank raised its stake in Momenta Pharmaceuticals by 16.1% in the 2nd quarter. Amalgamated Bank now owns 12,544 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 1,739 shares during the period. State of Wisconsin Investment Board raised its stake in Momenta Pharmaceuticals by 2.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 78,166 shares of the biotechnology company’s stock valued at $1,598,000 after acquiring an additional 2,066 shares during the period. Rhumbline Advisers raised its stake in Momenta Pharmaceuticals by 1.6% in the 2nd quarter. Rhumbline Advisers now owns 185,957 shares of the biotechnology company’s stock valued at $3,803,000 after acquiring an additional 2,913 shares during the period. Russell Investments Group Ltd. raised its stake in Momenta Pharmaceuticals by 16.7% in the 1st quarter. Russell Investments Group Ltd. now owns 21,669 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 3,100 shares during the period. Finally, Aperio Group LLC raised its stake in Momenta Pharmaceuticals by 17.0% in the 2nd quarter. Aperio Group LLC now owns 21,371 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 3,102 shares during the period. 95.98% of the stock is currently owned by institutional investors.

A number of equities analysts have issued reports on the stock. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. ValuEngine raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Cantor Fitzgerald set a $24.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, October 10th. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, October 8th. Finally, Stifel Nicolaus set a $39.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $27.00.

ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 4,374 Shares” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/13/momenta-pharmaceuticals-inc-mnta-ceo-craig-a-wheeler-sells-4374-shares.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Read More: How To Calculate Debt-to-Equity Ratio

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.